FDA批准的含γ-内酰胺药物（2011-2025）：合成与临床应用
FDA-approved γ-lactam-containing drugs (2011-2025): Synthesis and clinical applications.
摘要(中文译文)
γ-内酰胺是常出现于生物活性分子和药物活性成分中的优势杂环骨架。过去十五年间，关于γ-内酰胺的研究经历了显著增长，这清楚地反映在含有γ-内酰胺基序的FDA批准药物分子数量不断增加上。2011年至2025年间，美国食品药品监督管理局（FDA）共批准了八种含γ-内酰胺的小分子药物，其中包括一种吡咯烷-2,5-二酮，而此类批准在2011年之前鲜有报道。在本篇小型综述中，我们简要概述了2011年至2025年FDA批准的含γ-内酰胺药物，特别着重于其结构特征、原始合成策略和临床应用。此外，还简要讨论了γ-内酰胺类药物发展当前面临的挑战和未来前景。
Abstract
γ-Lactams are privileged heterocyclic scaffolds that frequently occur in biologically active molecules and pharmaceutical agents. Over the past fifteen years, research on γ-lactams has experienced significant growth, which is clearly reflected in the increasing number of FDA-approved drug molecules containing γ-lactam motifs. Eight γ-lactam-containing small-molecule drugs have been approved by the U.S. Food and Drug Administration (FDA) between 2011 and 2025, including one pyrrolidine-2,5-dione, whereas such approvals were rarely reported prior to 2011. In this mini-review, we provide a concise overview of FDA-approved γ-lactam-containing drugs from 2011 to 2025, with particular emphasis on their structural features, original synthetic strategies, and clinical applications. Current challenges and future perspectives for the development of γ-lactam-based drugs are also briefly discussed.
如何引用
AMA
Lei Yu, Qian Zhang, Nawaf Al-Maharik, Dong Li, Zeguo Fang. FDA-approved γ-lactam-containing drugs (2011-2025): Synthesis and clinical applications.. Bioorganic chemistry. 2026; doi:10.1016/j.bioorg.2026.110135.
APA
Lei Yu, Qian Zhang, Nawaf Al-Maharik, Dong Li, Zeguo Fang (2026). FDA-approved γ-lactam-containing drugs (2011-2025): Synthesis and clinical applications.. Bioorganic chemistry. https://doi.org/10.1016/j.bioorg.2026.110135
GB/T 7714
Lei Yu, Qian Zhang, Nawaf Al-Maharik, Dong Li, Zeguo Fang. FDA-approved γ-lactam-containing drugs (2011-2025): Synthesis and clinical applications.[J]. Bioorganic chemistry, 2026 doi:10.1016/j.bioorg.2026.110135.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出